Cd41a pe cy7 clone hip8

Manufactured by BD

CD41a-PE-Cy7 (clone HIP8) is a fluorochrome-conjugated monoclonal antibody that binds to the CD41a antigen expressed on the surface of platelets. The PE-Cy7 fluorescent label allows for the detection and analysis of CD41a-positive cells using flow cytometry techniques.

Automatically generated - may contain errors

Lab products found in correlation

4 6 diamidino 2 phenylindole (dapi), by Thermo Fisher Scientific (2 mentions) Cd33 pe cf594 clone wm53, by BD (2 mentions) Cytofix cytoperm plus kit, by BD (1 mentions) Cd34 pe clone 563, by BD (1 mentions) Cd45 apc clone hi30, by BD (1 mentions) Mcd45 pe cy7 clone 30 f11, by BD (1 mentions) Cd38 pe cf594 clone hit2, by BD (1 mentions) Facsaria 2, by BD (1 mentions) Cd34 pe, by BD (1 mentions) Cd4 pe cy7, by BD (1 mentions) Fortessa, by BD (1 mentions) Cd8 percp cy5, by BD (1 mentions) Cd14 apc clone m5e2, by BD (1 mentions)

Spelling variants of this product

Clone HIP8 (7 citations) CD41a (7 citations) CD41a-PE (4 citations) CD41a (HIP8) (2 citations)

2 protocols using cd41a pe cy7 clone hip8

Flow Cytometry Analysis of Hematopoietic Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Following hematopoietic differentiation, the cells were dissociated with accutase into single cells. The following flow cytometry antibodies were used: CD34-PE (clone 563, BD PharMingen), CD45-BV510 (clone HI30, BD Horizon), CD90-PerCP/Cy5.5 (clone 5E10, BioLegend), CD38-PE-CF594 (clone HIT2, BD Horizon), CD33-PE-CF594 (clone WM53, BD Horizon), CD49f-BV421 (clone GoH3, BD Horizon), CD45RA-APC (clone MEM56, Life Technologies), CD123-BV711 (clone 9F5, BD Horizon), CD41a- PE-Cy7 (clone HIP8, BD PharMingen), mCD45-PE-Cy7 (clone 30-F11, BD Biosciences), CD45-APC (clone HI30, BD PharMingen), CD19-PerCP-Cy5.5 (clone HIB19, BD PharMingen). Cell viability was assessed with DAPI (Life Technologies). Intracellular staining of Patient 65 cells was performed with a biotin-conjugated TSPAN18 antibody (Lifespan Bioscience) and a secondary ani-biotin APC antibody (Miltenyi Biotec) using the Cytofix/Cytoperm Plus kit (BD Biosciences). Cells were assayed on a BD Fortessa and data were analyzed with FlowJo software (Tree Star).

Wesely J., Kotini A.G., Izzo F., Luo H., Yuan H., Sun J., Georgomanoli M., Zviran A., Deslauriers A.G., Dusaj N., Nimer S.D., Leslie C., Landau D.A., Kharas M.G, & Papapetrou E.P. (2020). Acute Myeloid Leukemia iPSCs Reveal a Role for RUNX1 in the Maintenance of Human Leukemia Stem Cells. Cell reports, 31(9), 107688.

+ Open protocol

+ Expand

Flow Cytometry Antibody Staining

Check if the same lab product or an alternative is used in the 5 most similar protocols

For flow cytometry, the following antibodies were used: CD34-PE
(clone 563, BD Pharmingen), CD41a- PE-Cy7 (clone HIP8, BD Pharmingen),
CD90-PerCP/Cy5.5 (clone 5E10, BioLegend), CD45-APC (clone HI30, BD
Pharmingen), CD15-FITC (clone W6D3, BD Pharmingen), CD14-APC (clone M5E2, BD
Pharmingen), CD33-PE-CF594 (clone WM53, BD Horizon), CD235a-PerCP/Cy5.5
(clone HI264, BioLegend), CD7-BV510 (Clone M-T701, BD Horizon), CD4-PE-Cy7
(Clone RPA-T4, BD Pharmingen) and CD8-PerCP/Cy5.5 (Clone RPA-T8, BD
Pharmingen). Cell viability was assessed with DAPI (Life Technologies).
Cells were then assayed on a BD Fortessa and data were analyzed with FlowJo
software (Tree Star). Sorting of CD41a⁺ and
CD41a⁻ cells was performed on a BD FACS Aria II.

Kotini A.G., Chang C.J., Chow A., Yuan H., Ho T.C., Wang T., Vora S., Solovyov A., Husser C., Olszewska M., Teruya-Feldstein J., Perumal D., Klimek V.M., Spyridonidis A., Rampal R.K., Silverman L., Reddy E.P., Papaemmanuil E., Parekh S., Greenbaum B.D., Leslie C.S., Kharas M.G, & Papapetrou E.P. (2017). Stage-specific human induced pluripotent stem cells map the progression of myeloid transformation to transplantable leukemia. Cell stem cell, 20(3), 315-328.e7.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!